glp-1/gip dual agonist mechanism of action Frontiers Mechanisms of action of GLP-1

Description

This review focuses on how GLP-1RAs impact lipid-related outcomes

Are GLP-1 drugs an 'existential threat' to the food industry or an opportunity to cash in with 'companion' products and 'Nature's Ozempic'?

Do not exceed recommended serving

Conclusions To conclude, reduced Cmax and delayed tmax of drugs co-administered with GLP1RAs are consistent with the known delayed gastric output by the latter

GLP-1 RAs have been shown to result in increased residual gastric contents (RGCs) in patients undergoing EGDs and poor Boston Bowel Preparation Scores (BBPSs) in those undergoing colonoscopies